RBC Capital Maintains Sector Perform on Marinus Pharma, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a Sector Perform rating on Marinus Pharma (NASDAQ:MRNS) but has lowered the price target from $3 to $1.
October 25, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained a Sector Perform rating on Marinus Pharma but significantly lowered the price target from $3 to $1, indicating a bearish outlook.
The significant reduction in the price target from $3 to $1 by RBC Capital suggests a bearish outlook on Marinus Pharma's stock. This could lead to a negative short-term impact on the stock price as investors may react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100